- Supported exchanges /
- PINK /
- HUMDF.PINK
Hua Medicine (Shanghai) Ltd (HUMDF PINK) stock market data APIs
Hua Medicine (Shanghai) Ltd. operates as a drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. The company also offers Dorzagliatin in combination with GLP1RA for T2D and obesity; in combination with insulin to treat Type 1 Diabetes; second generation glucokinase (GK) inhibitor for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and GK NAM for metabolic disease. The company was incorporated in 2011 and is based in Shanghai, China.
Hua Medicine (Shanghai) Ltd Financial Data Overview
0.2028 | |
0.2028 | |
- | |
0.2028 | |
0.2028 | |
0.2028-0.2028 | |
223 M | |
981 M | |
109 M | |
1.562 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Hua Medicine (Shanghai) Ltd Fundamental Data is available in our Financial Data APIs
- Net Revenue 109 M
- EBITDA -382 969 984
- Earnings Per Share -0.03
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Hua Medicine (Shanghai) Ltd Earnings via APIs
- Latest Release 2024-08-29
- EPS/Forecast NaN
Get Hua Medicine (Shanghai) Ltd End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: